|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.06.25 - 09:09
|
Takeda Announces New Assignments of Directors (Business Wire)
|
|
|
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today.
Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs.
Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company's values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success.
Details of the new assignments are as follows:
1. New Assignment of Directo...
|
|
|
|
|
|
|
|
|
|
|
04.06.25 - 17:03
|
Biocom California Appoints New Members to Its Board of Directors and Board of Governors (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today announced the appointment of Thierry Diagana, Ph.D., head of Global Health and California sites head for Novartis Biomedical Research; Stephen Hatke, vice president of operations and site head at Takeda's Thousand Oaks facility; and Kelly Hayes, assurance partner at Ernst & Young, to its board of directors. Additionally, Adam Lenain, member at Mintz Levin; Aaron K. Cohen, vice president, government affairs and public policy at Neurocrine Biosciences; and Diane Simeone, M.D., director of the Moores Cancer Center at University of California San Diego, were appointed to the board of governors.
“The addition of these accomplished leaders, scientists and policy changers brings strategic depth to our board of directors and board of governors,” said Tim Scott, president and CEO of Biocom California. “Their expertise in capital raising, public p...
|
|
|
|
|
|
|
26.05.25 - 05:01
|
Chisato Iwai Clinches Her 1st LPGA Victory (Nippon)
|
|
|
Playa del Carmen, Mexico, May 25 (Jiji Press)--Chisato Iwai won the Mexico Riviera Maya Open by six shots on Sunday, clinching her first LPGA title. The 22-year-old finished at 12-under 276 at El Camaleon, becoming the third Japanese woman to claim an LPGA title this season after Rio Takeda and Mao Saigo. "I'm very delighted" Iwai said. "Despite a wide lead, my feelings didn't change.......
|
|
|
22.05.25 - 14:03
|
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park (Business Wire)
|
|
|
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology.
TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base.
To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary.
Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was devel...
|
|
|
|
|
|
|
|
|
08.05.25 - 08:39
|
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress (Business Wire)
|
|
|
Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024
Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings
Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated
FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation
Proposed Dividend Increase from JPY 196 to JPY 200
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.
Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
